Product Description
For open-angle glaucoma or ocular hypertension (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01318252)
Mechanisms of Action: EP2 Stimulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alcon
Company Location: Europe
Company Founding Year: 1945
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypertension|Glaucoma, Open-Angle
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01318252 |
C-10-080 | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2011-10-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|